Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 16, 2024 - Issue
Submit an article Journal homepage
105
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Sergio Di Matteo1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, ItalyView further author information
,
Roberto Freilone2 Dipartimento di Oncologia - Direttore SC Ematologia, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino e componente Tumor Molecular Board (TMB) Regione Piemonte, Torino, ItalyView further author information
,
Giacomo Matteo Bruno1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy;3 Department of Drug Sciences, University of Pavia, Pavia, ItalyORCID Iconhttps://orcid.org/0000-0003-4571-654XView further author information
ORCID Icon,
Rosario Notaro4 Direttore S.C. Core Research Laboratory in ISPRO, Firenze, ItalyView further author information
,
Sabrin Moumene1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, ItalyView further author information
,
Nicoletta Martone5 Sobi S.r.l., Milano, ItalyView further author information
,
Cristina Teruzzi5 Sobi S.r.l., Milano, ItalyView further author information
,
Antonio Ciccarone1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, ItalyView further author information
&
Giorgio Lorenzo Colombo1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy;3 Department of Drug Sciences, University of Pavia, Pavia, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5790-8891View further author information
ORCID Icon show all
Pages 225-232 | Received 31 Oct 2023, Accepted 26 Mar 2024, Published online: 10 Apr 2024

References

  • Colden MA, Kumar S, Munkhbileg B, et al. Insights into the emergence of paroxysmal nocturnal hemoglobinuria. Front Immunol. 2022;12(gennaio):830172. doi:10.3389/fimmu.2021.830172
  • Merck & Co. MSD manuals professional edition. s.d. Available from: https://www.msdmanuals.com/it-it/professionale. Accessed August 28, 2023.
  • Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Prim. 2017;3(1):17028. doi:10.1038/nrdp.2017.28
  • De Fontbrune S, Flore PB, Piggin M, et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective. Hematology. 2022;27(1):1140–1151. doi:10.1080/16078454.2022.2127630
  • Shah N, Bhatt EH. Paroxysmal nocturnal hemoglobinuria. National Library of Medicine; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562292/. Accessed March 27, 2024.
  • Hakimi Z, Wilson K, McAughey E, et al. The cost–effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting. J Comp Eff Res. 2022;11(13):969–985. doi:10.2217/cer-2022-0076
  • Bhak RH, Mody-Patel N, Baver SB, et al. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Curr Med Res Opin. 2021;37(11):1913–1923. doi:10.1080/03007995.2021.1971182
  • FDA approves new treatment for adults with serious rare blood disease | FDA. s.d. Consultato 4 agosto 2023. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-adults-serious-rare-blood-disease. Accessed March 27, 2024.
  • Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037. doi:10.1056/NEJMoa2029073
  • Aspaveli | European medicines agency. s.d. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli. Accessed August 4th, 2023.
  • Drabo EF, Padula WV. Introduction to Markov modeling. In: David B, Logan B, William VP, editors. Handbook of Applied Health Economics in Vaccines. Oxford University Press. © Oxford University Press;2023. doi:10.1093/oso/9780192896087.003.0022
  • Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 Study. Blood. 2019;133(6):540–549. doi:10.1182/blood-2018-09-876805
  • Longworth L, Yang Y, Young T, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9). doi:10.3310/hta18090
  • Lloyd AJ, Gallop K, Ali S. PSY9 preference weights for quality-adjusted life-years estimation for treatments of paroxysmal nocturnal hemoglobinuria in the United Kingdom. Value Health. 2019;22(November):S902. doi:10.1016/j.jval.2019.09.2637
  • Stoner KL, Harder H, Fallowfield LJ, et al. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient. 2015;8(2):145–153. doi:10.1007/s40271-014-0075-y
  • Catalano L. Italian blood system 2021: activity data, haemovigilance and epidemiological surveillance. ISTISAN Reports, Available from: www.iss.it/documents/20126/6682486/22-25+web.pdf/192d899e-0afe-c3f7-c52df373a89097e2?t=1667829051240. Accessed March 27, 2024.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.